Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinicopathologic correlation in IgA nephropathy.

David Philibert1, Daniel Cattran, Terence Cook

  • 1University Health Network, Toronto General Research Institute, Toronto, Canada.

Seminars in Nephrology
|January 29, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictive Value of the Oxford Classification for the Effect of Glucocorticoid Therapy in IgA Nephropathy.

Journal of the American Society of Nephrology : JASN·2025
Same author

Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial.

Clinical journal of the American Society of Nephrology : CJASN·2024
Same author

Pembrolizumab-Induced Anti-GBM Glomerulonephritis: A Case Report.

Kidney medicine·2023
Same author

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.

Kidney international·2022
Same author

Racial and Ethnic Disparities in Acute Care Utilization Among Patients With Glomerular Disease.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2022
Same author

Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

JAMA·2022
Same journal

Current Options for Kidney Protection: Are Renin-Angiotensin System Inhibitors Still Relevant?

Seminars in nephrology·2026
Same journal

Proposed Role for Quantitative Podocyturia as a Clinical Marker of Systemic Endothelial Injury: Implications for Cardiovascular Disease and Longevity.

Seminars in nephrology·2026
Same journal

Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?

Seminars in nephrology·2026
Same journal

From Nephron Number to Global Health.

Seminars in nephrology·2026
Same journal

Chronic Kidney Disease Progression Mechanisms: Why They Matter in an Era of Novel Kidney Protective Therapies.

Seminars in nephrology·2026
Same journal

Of Diuretics, Transporters, and Mechanisms of Hypertension.

Seminars in nephrology·2026
See all related articles

IgA nephropathy, a common kidney disease, presents with varied symptoms. Prognosis depends on clinical and histologic factors, highlighting the need for tailored patient management.

Area of Science:

  • Nephrology
  • Immunopathology

Background:

  • Immunoglobulin A (IgA) nephropathy is the leading cause of glomerulonephritis worldwide.
  • Prognosis is influenced by diverse clinical and histological factors.

Observation:

  • This review examines four distinct IgA nephropathy cases.
  • Presentations included modest proteinuria, acute kidney injury, and nephrotic syndrome.

Findings:

  • IgA nephropathy exhibits significant clinical heterogeneity.
  • Clinical presentation impacts patient outcomes and management strategies.

Implications:

  • Understanding varied presentations is crucial for accurate diagnosis and prognosis in IgA nephropathy.
  • Tailored therapeutic approaches based on clinical-pathologic findings are essential.

Related Experiment Videos